StockUS listing USKKPCFPINKHealthcareDefensive Anchor

Kaken Pharmaceutical Co. Ltd(KKPCF) Stock Analysis | Healthcare

USD --+0.00%
Reward64Moderate
Risk12Low
75%Data
Thin -5% profit margin · 5.0% dividend yield · Revenue down 26% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 1.07Bn
Reward Ratingⓘ64 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ12 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on KKPCF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Kaken Pharmaceutical Co. Ltd?

produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally.

AI Brief Pro

The brief on Kaken Pharmaceutical Co. Ltd

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Kaken Pharmaceutical Co. Ltd?

produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.07B, and a P/E ratio of 288.9x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (64)

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
P/E Ratio288.8889
Beta0.065
Insider Activity
12M windowNo data
No insider activity data available for this ticker.